A roadmap for psychedelic pharmacy in Canada: A proposed policy and operations approach for controlled access to select psychedelics for treatment of mental illness
Drug Science Policy and Law 2023 DOI: 10.1177/20503245231170340 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Perspective commentary Case report Peer reviewed |
|---|---|
| Topics | Psilocybin |
| Keywords | Pharmacy Mental illness Legislature Mental health Perspective graphical Public relations Health care Public administration Nursing Hallucinogen Law |
| Citations | 5 |
| Key points | Argues that the pharmacy profession has had little engagement in the development of policies and practices for psychedelic medicine, and proposes strategies for legal reform, regulatory policy, and pharmacy operations using Canada as a case study. |
Abstract
The unprecedented progress in the science and clinical investigation of psychedelic medicine will require those in healthcare leadership and the legislative policy arena to conceptualize how future reforms, policy creation, and clinical practice should occur to broaden access to these agents while simultaneously maximizing effectiveness and mitigating harm. The pharmacy profession has surprisingly had little engagement on this front. This article provides a perspective commentary and overview of potential future strategies in legal reform, professional regulatory authority policy creation, and pharmacy operations regarding the psychedelic agents’ psilocybin and methylenedioxymethamphetamine, using Canada as a national case study.